CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) in Adults With Recurrent Glioblastoma Multiforme (GBM)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04489420
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:02.197399+00:00
Published At: 2022-08-10T00:00:00+00:00
Record Updated At: 2022-08-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Astrocytoma, Grade IV", "Giant Cell Glioblastoma", "Glioblastoma Multiforme", "Cyclophosphamide", "Immunosuppressive Agents", "Immunologic Factors", "Physiological Effects of Drugs", "Molecular Mechanisms of Pharmacological Action", "Antiviral Agents", "Anti-infective Agents", "Analgesics, Non-narcotic", "Analgesics", "Sensory System Agents", "Peripheral Nervous System Agents"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-08-10"
protocolSection.identificationModule.nctId: "NCT04489420"
protocolSection.identificationModule.officialTitle: "A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) in Adults With Recurrent Glioblastoma Multiforme (GBM)"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.